Cancer Imaging
癌症影像
基本信息
- 批准号:10626977
- 负责人:
- 金额:$ 9.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-06-04 至 2027-05-31
- 项目状态:未结题
- 来源:
- 关键词:AccountingAnimal Disease ModelsBiological ProcessBioluminescenceBudgetsCancer BiologyCancer Center Support GrantConsultCyclotronsData AnalysesDetectionDiagnosticDiscipline of Nuclear MedicineDisease ProgressionDoctor of PhilosophyEducational workshopEnsureExperimental DesignsFacultyFluorescenceFosteringFundingGoalsHematologic NeoplasmsImageImaging DeviceImaging technologyImmunologyIndividualInstitutionKnowledgeLaboratoriesMagnetic Resonance ImagingMagnetismMalignant NeoplasmsMedicalMedical ImagingMolecular BiologyMonitorOncologyPhysicsPlayPositron-Emission TomographyPublicationsRadiobiologyRadiochemistryResearchResearch PersonnelResource SharingRoleScientistScreening for cancerServicesSiteTechnologyTherapeuticTracerTrainingTranslational ResearchWorkX-Ray Computed Tomographyanimal facilityanimal imaginganticancer researchassay developmentcancer imagingcancer immunotherapycancer stem celldrug developmentexperienceimaging modalityimaging scientistimprovedin vivoin vivo imaginginstrumentmembermolecular imagingnovel diagnosticsnovel therapeutic interventionoptical imagingparticlepre-clinical researchpreclinical imagingprogramstheranosticsultrasound
项目摘要
PROJECT SUMMARY
The Cancer Imaging Shared Resource (CI-SR) provides advanced preclinical imaging technologies and services
for studying cancer biology, early cancer detection, monitoring disease progression, and developing novel
diagnostic and theranostic agents. All major small animal imaging modalities are available, including positron
emission tomography (PET), magnetic resonance imaging (MRI), x-ray computed tomography (CT), ultrasound
and photoacoustics, magnetic particle imaging (MPI), and optical imaging (e.g., bioluminescence, fluorescence,
Cerenkov). Since the last review, the CI-SR has acquired new and upgraded imaging instruments, including the
first-of-its-kind MPI scanner. In 2020, 54% of users were SCI investigators accounting for approximately 55% of
total usage. Members of the Cancer Imaging, Cancer Biology and Cancer Stem Cells, Cancer Therapeutics,
Radiation Biology, Cancer Immunotherapy, and Hematologic Malignancies programs regularly use the CI-SR,
with the heaviest use coming from the Cancer Imaging, Cancer Biology and Cancer Stem Cells, and Cancer
Therapeutics programs. The CI-SR contributed to over 55 cancer-focused publications (15 high-impact). The
annual budget of the CI-SR is $1,021,174, yet the CCSG request is $106,372. Accordingly, the CI-SR leverages
extensive institutional support and seeks 10% from CCSG funds. The CI-SR is focused on two major scientific
aims: (1) to provide access to state-of-the-art and first-of-its-kind in vivo imaging technologies and services
pertinent to cancer research and (2) to educate, train, and consult with SCI members in basic and advanced
imaging methods and data analysis through training courses, seminars, and workshops.
项目摘要
癌症成像共享资源(CI-SR)提供先进的临床前成像技术和服务
研究癌症生物学,早期癌症检测,监测疾病进展,并开发新的
诊断和治疗诊断剂。所有主要的小动物成像模式都可用,包括正电子
发射断层扫描(PET)、磁共振成像(MRI)、x射线计算机断层扫描(CT)、超声
以及光声、磁粒子成像(MPI)和光学成像(例如,生物发光,荧光,
切伦科夫)。自上次审查以来,CI-SR已获得新的和升级的成像仪器,包括
第一台MPI扫描仪2020年,54%的用户是SCI调查人员,约占
全部使用。癌症成像,癌症生物学和癌症干细胞,癌症治疗,
放射生物学、癌症免疫治疗和血液肿瘤项目定期使用CI-SR,
其中使用最多的是癌症成像,癌症生物学和癌症干细胞,以及癌症
治疗方案。CI-SR贡献了超过55篇以癌症为重点的出版物(15篇影响力大)。的
CI-SR的年度预算为1,021,174美元,而CCSG的要求为106,372美元。因此,CI-SR利用
广泛的机构支持,并寻求CCSG资金的10%。CI-SR侧重于两个主要的科学
目标:(1)提供最先进和最先进的体内成像技术和服务
与癌症研究有关;(2)教育,培训和咨询SCI成员的基础和高级
通过培训课程、研讨会和讲习班,提供成像方法和数据分析。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jason Thanh Lee其他文献
Jason Thanh Lee的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jason Thanh Lee', 18)}}的其他基金
Pre-clinical Bruker Albira Si PET/SPECT/CT imaging system
临床前 Bruker Albira Si PET/SPECT/CT 成像系统
- 批准号:
10633022 - 财政年份:2023
- 资助金额:
$ 9.19万 - 项目类别:
相似海外基金
Investigating how TRAF1 Controls Inflammasome Activation in Animal Disease Models of Inflammatory Arthritis and Peritonitis
研究 TRAF1 如何控制炎症性关节炎和腹膜炎动物疾病模型中的炎症小体激活
- 批准号:
449429 - 财政年份:2020
- 资助金额:
$ 9.19万 - 项目类别:
Studentship Programs
Establishment of animal disease models for intractable pediatric diseases due to defects of RNA metabolism and development of new therapeutics
RNA代谢缺陷引起的儿科疑难疾病动物模型的建立及新疗法的开发
- 批准号:
20H03644 - 财政年份:2020
- 资助金额:
$ 9.19万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Functional analysis of type 2 diabetes susceptibility genes using animal disease models
利用动物疾病模型对2型糖尿病易感基因进行功能分析
- 批准号:
18K08466 - 财政年份:2018
- 资助金额:
$ 9.19万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Cell therapy of adipocytes derived from human iPS cells using cellcontainers and animal disease models
使用细胞容器和动物疾病模型对源自人类 iPS 细胞的脂肪细胞进行细胞治疗
- 批准号:
24659444 - 财政年份:2012
- 资助金额:
$ 9.19万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Analysis of genes involved in the pathogenesis of the arthritis using animal disease models..
使用动物疾病模型分析涉及关节炎发病机制的基因。
- 批准号:
17500284 - 财政年份:2005
- 资助金额:
$ 9.19万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
ESTABLISHMENT OF THE DEVELOPING AND SUPPLING SYSTEMS FOR NEW ANIMAL,DISEASE MODELS FROM SUBSPECIES OF THE MOUSE
小鼠亚种新动物、疾病模型的开发和供应体系的建立
- 批准号:
07556128 - 财政年份:1995
- 资助金额:
$ 9.19万 - 项目类别:
Grant-in-Aid for Scientific Research (A)